{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-005194","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.418782+00:00","generated_at":"2026-05-31T13:48:14.360207+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Phio Pharmaceuticals appoints Robert Infarinato as CFO effective August 1, 2024","bullets":["Robert M. Infarinato appointed VP & CFO effective August 1, 2024; will serve as principal financial and accounting officer.","Mr. Infarinato, 78, is an attorney and CPA with over 20 years of financial leadership in pharma and biotech.","Base salary $180,000; eligible for annual bonus up to 30% of base based on performance goals.","Caitlin Kontulis ceased as principal accounting officer on August 1 and will leave employment on August 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-005194","json":"https://secwatch.observer/filing/0001683168-24-005194.json","markdown":"https://secwatch.observer/filing/0001683168-24-005194.md","text":"https://secwatch.observer/filing/0001683168-24-005194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/0001683168-24-005194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:48:14.360207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2423348417","claim":"Caitlin Kontulis departed as Vice President of Finance and Administration and Secretary at Phio Pharmaceuticals Corp..","evidence_excerpt":"Caitlin Kontulis, Vice President of Finance and Administration and Secretary of the Company, ceased serving as the Company’s principal accounting officer, effective as of August 1, 2024, with her employment terminating on August 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/0001683168-24-005194-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Vice President of Finance and Administration and Secretary"}],"fact_type":"executive_change"},{"claim_id":"2e241b5e11","claim":"Robert M. Infarinato was appointed as Vice President, Chief Financial Officer at Phio Pharmaceuticals Corp..","evidence_excerpt":"On July 15, 2024, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert M. Infarinato to serve as the Company’s Vice President, Chief Financial Officer and designated him as the Company’s principal financial officer and principal accounting officer, effective as of August 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824005194/0001683168-24-005194-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President, Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}